Year |
Citation |
Score |
2014 |
Busch AM, Galimberti F, Nehls KE, Roengvoraphoj M, Sekula D, Li B, Guo Y, Direnzo J, Fiering SN, Spinella MJ, Robbins DJ, Memoli VA, Freemantle SJ, Dmitrovsky E. All-trans-retinoic acid antagonizes the Hedgehog pathway by inducing patched. Cancer Biology & Therapy. 15: 463-72. PMID 24496080 DOI: 10.4161/Cbt.27821 |
0.733 |
|
2013 |
Busch AM, Johnson KC, Stan RV, Sanglikar A, Ahmed Y, Dmitrovsky E, Freemantle SJ. Evidence for tankyrases as antineoplastic targets in lung cancer. Bmc Cancer. 13: 211. PMID 23621985 DOI: 10.1186/1471-2407-13-211 |
0.723 |
|
2012 |
Galimberti F, Busch AM, Chinyengetere F, Ma T, Sekula D, Memoli VA, Dragnev KH, Liu F, Johnson KC, Guo Y, Freemantle SJ, Andrew AS, Greninger P, Robbins DJ, Settleman J, et al. Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations. International Journal of Oncology. 41: 1751-61. PMID 22923130 DOI: 10.3892/Ijo.2012.1599 |
0.658 |
|
2012 |
Busch AM, Johnson KC, Tacchelly O, Wang Z, Ahmed YF, Dmitrovsky E, Freemantle SJ. Abstract 973: Tankyrase inhibition represses Wnt signaling and lung cancer growth Cancer Research. 72: 973-973. DOI: 10.1158/1538-7445.Am2012-973 |
0.725 |
|
2011 |
Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer M, Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, et al. Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prevention Research (Philadelphia, Pa.). 4: 818-28. PMID 21636548 DOI: 10.1158/1940-6207.Capr-10-0376 |
0.734 |
|
2011 |
Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer MA, Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, et al. Abstract LB-412: Combining bexarotene with erlotinib in window of opportunity and phase II trials causes lung cancer responses independent of KRAS mutations Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-412 |
0.739 |
|
2010 |
Guo Y, Dolinko A, Chinyengetere F, Bomberger J, Gallagher R, Ma T, Galimberti F, Liu X, Sekula D, Busch A, Freemantle S, Dmitrovsky E. Abstract 1594: Targeting UBP43 for repression destabilizes PML/RARα and inhibits acute promyelocytic leukemia growth Cancer Research. 70: 1594-1594. DOI: 10.1158/1538-7445.Am10-1594 |
0.631 |
|
2009 |
Snow GE, Kasper AC, Busch AM, Schwarz E, Ewings KE, Bee T, Spinella MJ, Dmitrovsky E, Freemantle SJ. Wnt pathway reprogramming during human embryonal carcinoma differentiation and potential for therapeutic targeting. Bmc Cancer. 9: 383. PMID 19874621 DOI: 10.1186/1471-2407-9-383 |
0.592 |
|
Show low-probability matches. |